Difference between revisions of "P2Y purinoceptor 12"
(Created page with "{| align="left" | __TOC__ |} {{#invoke:InfoboxforTarget|run|P2Y12, ADPG-R|[https://www.uniprot.org/uniprot/Q9H244 Q9H244]|Homo sapiens|Cys17, Cys270|[http://pfam.xfam.org/...") |
(No difference)
|
Revision as of 15:37, 17 August 2019
Basic Information | |
---|---|
Short Name | P2Y12, ADPG-R |
UNP ID | Q9H244 |
Organism | Homo sapiens |
Cys Site | Cys17, Cys270 |
Family/Domain |
7 transmembrane receptor (rhodopsin family), G-protein coupled receptor 1 family] |
Known Ligand | Ligand list |
Function Type | G-protein coupled receptor |
Summary
Protein Function
In the field of purinergic signaling, the P2Y12 protein is found mainly but not exclusively on the surface of blood platelets, and is an important regulator in blood clotting. P2Y12 belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors and is a chemoreceptor for adenosine diphosphate (ADP). The P2Y family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is involved in platelet aggregation, and is a potential target for the treatment of thromboembolisms and other clotting disorders.
The drugs clopidogrel (Plavix), prasugrel (Efient, Effient) ticagrelor (Brilinta) and cangrelor (Kengreal) bind to this receptor and are marketed as antiplatelet agents. P2Y12 inhibitors do not change the risk of death when given to people who have had a NSTEMI. They do however increase the risk of bleeding and decrease the risk of further cardiovascular problems. Thus their routine use is of questionable value. (From Wikipedia)
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. (From Uniprot)
Cys Function & Property
Cys17 and Cys270 are located at the extracellular regions of P2Y12, and could form disulfide bond
- Hydrophobic property:
- SASA:
- Cys17: 26.597 A^2
- Cys270: 44.767 A^2
Protein Sequence
MQAVDNLTSA PGNTSLCTRD YKITQVLFPL LYTVLFFVGL ITNGLAMRIF
FQIRSKSNFI IFLKNTVISD LLMILTFPFK ILSDAKLGTG PLRTFVCQVT
SVIFYFTMYI SISFLGLITI DRYQKTTRPF KTSNPKNLLG AKILSVVIWA
FMFLLSLPNM ILTNRQPRDK NVKKCSFLKS EFGLVWHEIV NYICQVIFWI
NFLIVIVCYT LITKELYRSY VRTRGVGKVP RKKVNVKVFI IIAVFFICFV
PFHFARIPYT LSQTRDVFDC TAENTLFYVK ESTLWLTSLN ACLDPFIYFF
LCKSFRNSLI SMLKCPNSAT SLSQDNRKKE QDGGDPNEET PM
Structural Information
- Known structure with covalent ligand:
- Unknown
- Protein structure:
Related Pathway
Experimental Evidence
- Cys-directed Mutation
Reference
- Ding Z, Kim S, Dorsam R T, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270[J]. Blood, 2003, 101(10): 3908-3914. 12560222